When Will Retatrutide Be Available?

As of 2025, retatrutide is in Phase 3 clinical trials conducted by Eli Lilly. Phase 3 is the final stage of human testing required before a pharmaceutical company can submit a New Drug Application (NDA) to the FDA. These trials are large-scale studies involving thousands of participants across multiple sites, designed to confirm efficacy and safety in diverse populations.

The Phase 3 program for retatrutide includes multiple trials evaluating the drug for obesity, type 2 diabetes, and potentially other metabolic conditions. The exact number and scope of these trials have not been fully disclosed, but they are expected to run for 12 to 24 months or longer.

The typical drug development timeline from Phase 3 completion to FDA approval involves several steps:

Phase 3 trial completion: 12-24+ months of active treatment, followed by data analysis NDA submission: Several months to compile the application FDA review: Standard review takes approximately 10-12 months; priority review takes 6-8 months

Based on this timeline, the earliest realistic window for FDA approval of retatrutide is likely in the 2027-2028 range, though this is speculative and subject to change. Delays in trial enrollment, unexpected safety signals, or FDA requests for additional data could extend the timeline further.

Eli Lilly has not publicly announced a specific target date for NDA submission. Investors and analysts monitor Eli Lilly's quarterly earnings calls and pipeline updates for hints about the expected timeline.

Even after FDA approval, there is typically a gap between the approval announcement and widespread availability. The manufacturer must ramp up production, negotiate pricing, secure pharmacy distribution channels, and work with insurance companies on coverage decisions. For recent GLP-1 medications, this gap has been relatively short -- Zepbound (tirzepatide for weight loss) became available within weeks of its November 2023 approval.

However, supply constraints have been a significant challenge for the GLP-1 class. Both semaglutide and tirzepatide experienced extended shortage periods due to overwhelming demand. If retatrutide shows the dramatic weight loss results in Phase 3 that Phase 2 suggested, demand could be enormous from day one.

The only legitimate way to access retatrutide before FDA approval is through enrollment in an active clinical trial. ClinicalTrials.gov lists ongoing Eli Lilly trials for retatrutide, and some may still be enrolling participants. Trial participants receive the medication at no cost and receive close medical monitoring.

Retatrutide is not available through any pharmacy, compounding facility, or online source. Any entity claiming to sell retatrutide for human use outside of a clinical trial is operating illegally. These products may be counterfeit, contaminated, or incorrectly dosed and pose serious health risks. There are no FDA-approved compounded versions of retatrutide because the drug itself has not been approved.

If you are interested in weight management with GLP-1 medications, effective options are available today. Semaglutide and tirzepatide have both been FDA-approved and extensively studied, with compounded versions available from licensed pharmacies at accessible price points. These medications use the same GLP-1 receptor pathway that retatrutide targets, and they deliver clinically meaningful weight loss for the majority of patients.